Nalaganje...
Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis
Paricalcitol and cinacalcet have been recommended to reduce parathyroid hormone (PTH) levels for patients with secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD), and they are able to reduce the risk of hypercalcemia and hyperphosphatemia. However, to date, it has remained uncerta...
Shranjeno v:
| izdano v: | Exp Ther Med |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
D.A. Spandidos
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7444362/ https://ncbi.nlm.nih.gov/pubmed/32855693 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/etm.2020.9044 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|